# US 2016/0256594 A1 · Emulsions or microemulsions for use in endoscopic mucosal resectioning and/or endoscopic submucosal dissection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256594 A1
- Document ID: US20160256594A1
- Status: Published application
- Kind: A1
- Application number: 15/154,857
- Filed: 2016-05-13
- Published: 2016-09-08
- Earliest claimed: 2013-11-20
- Assignees: Cosmo Technologies Limited
- Applicants: Cosmo Technologies Ltd.
- Inventors: Luigi MORO; Luigi Maria LONGO; Enrico FRIMONTI; Alessandro REPICI
- Web page: https://patentgrep.com/patent/US20160256594A1

## CPC

- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 49/006: {Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery}
- A61L 24/0005: {Ingredients of undetermined constitution or reaction products thereof}
- A61L 24/001: {Use of materials characterised by their function or physical properties}
- A61L 24/046: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds (A61L24/043 takes precedence)}
- A61L 31/06: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds {(A61L31/041 takes precedence)}
- A61L 31/14: Materials characterised by their function or physical properties {, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials}
- A61P 41/00: Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A61L 2300/442: Colorants, dyes
- A61L 2400/06: Flowable or injectable implant compositions
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a pharmaceutical composition in form of emulsion or microemulsion and the use thereof as aid during endoscopic procedures in which it is injected in a target tissue in order to form a cushion. More in details, the invention relates to a method for performing an endoscopic procedure, which comprises injecting said pharmaceutical composition in form of emulsion or microemulsion in a target tissue of a patient, in order to form a cushion, which cushion is then optionally subjected to an endoscopic surgical procedure, such as a resection.

## Claims

### Claim 1

A pharmaceutical composition in the form of an emulsion or a microemulsion comprising:
(a) an aqueous phase;
(b) an oily phase;
(c) at least one surfactant;
(d) at least one of poloxamer 188, poloxamer 407 or a mixture of poloxamer 188 and poloxamer 407; and
(e) at least one physiologically acceptable excipient;
wherein said at least one of poloxamer 188, polyoxamer 407 or a mixture of poloxamer 188 and poloxamer 407 is present in an amount below the critical gelation concentration (CGC), and wherein said composition remains in liquid phase at a temperature between about 5° C. and about 40° C. in vitro.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein said composition has a viscosity below about 150 cP (centipoises).

### Claim 3 (depends on 1)

The pharmaceutical composition according to claim 1, wherein said at least one of poloxamer 188, poloxamer 407 or a mixture of poloxamer 188 and poloxamer 407 is present in an amount below about 15% by weight, with respect to the weight of the composition.

### Claim 4 (depends on 1)

The pharmaceutical composition in form of emulsion or microemulsion according to claim 1, wherein said at least one of poloxamer 188, polyoxamer 407 or a mixture of poloxamer 188 and poloxamer 407 is present in an amount between about 5% and about 11% by weight, with respect to the weight of the composition.

### Claim 5 (depends on 1)

The pharmaceutical composition according to claim 1, wherein said poloxamer 407 is present in an amount of about 9% by weight with respect to the weight of the composition.

### Claim 6 (depends on 1)

The pharmaceutical composition according to claim 1, wherein said poloxamer 188 is present in an amount of about 10% by weight with respect to the weight of the composition.

### Claim 7 (depends on 1)

The pharmaceutical composition according to claim 1, wherein said mixture of poloxamer 188 and poloxamer 407 is present in an amount of about 10% by weight with respect to the weight of the composition.

### Claim 8 (depends on 1)

The pharmaceutical composition according to claim 1, wherein said oily phase comprises at least one lipophilic compound.

### Claim 9 (depends on 8)

The pharmaceutical composition according to claim 8, wherein said at least one lipophilic compound is selected from medium-chain triglycerides and soybean oil.

### Claim 10 (depends on 1)

The pharmaceutical composition according to claim 1, wherein said at least one surfactant is at least one non-ionic surfactant.

### Claim 11 (depends on 10)

The pharmaceutical composition according to claim 10, wherein said at least one non-ionic surfactant is selected from polysorbate 80 and PEG-15 hydroxystearate.

### Claim 12 (depends on 1)

The pharmaceutical composition according to claim 1, wherein said at least one surfactant is at least one ionic surfactant.

### Claim 13 (depends on 12)

The pharmaceutical composition according to claim 12, wherein said at least one ionic surfactant is selected from egg lecithin, hydrogenated phosphatidyl choline from egg lecithin, soybean lecithin and hydrogenated soybean lecithin.

### Claim 14 (depends on 1)

The pharmaceutical composition according to claim 1, wherein said pharmaceutical composition contains at least one co-surfactant selected from propylene glycol, glycerol and sodium oleate.

### Claim 15 (depends on 1)

The pharmaceutical composition according to claim 1, wherein said pharmaceutical composition further comprises at least one dye.

### Claim 16 (depends on 15)

The pharmaceutical composition according to claim 15, wherein said at least one dye is methylene blue or indigo carmine.

### Claim 17 (depends on 1)

The pharmaceutical composition according to claim 1, wherein
said oily phase comprises at least one lipophilic compound selected from medium-chain triglycerides and soybean oil and
said at least one surfactant is at least one non-ionic surfactant selected from polysorbate 80 and PEG-15 hydroxystearate.

### Claim 18 (depends on 17)

The pharmaceutical composition according to claim 17, wherein said pharmaceutical composition contains at least one co-surfactant selected from propylene glycol, glycerol and sodium oleate.

### Claim 19 (depends on 17)

The pharmaceutical composition according to claim 17, wherein said pharmaceutical composition further comprises at least one dye.

### Claim 20 (depends on 19)

The pharmaceutical composition according to claim 19, wherein said at least one dye is methylene blue or indigo carmine.

### Claim 21 (depends on 1)

The pharmaceutical composition according to claim 1, wherein
said oily phase comprises at least one lipophilic compound selected from medium-chain triglycerides and soybean oil and
said at least one surfactant is at least one ionic surfactant selected from egg lecithin, hydrogenated phosphatidyl choline from egg lecithin, soybean lecithin and hydrogenated soybean lecithin.

### Claim 22 (depends on 21)

The pharmaceutical composition according to claim 21, wherein said pharmaceutical composition contains at least one co-surfactant selected from propylene glycol, glycerol and sodium oleate.

### Claim 23 (depends on 21)

The pharmaceutical composition according to claim 21, wherein said pharmaceutical composition further comprises at least one dye.

### Claim 24 (depends on 23)

The pharmaceutical composition according to claim 23, wherein said at least one dye is methylene blue or indigo carmine.
